Your browser doesn't support javascript.
loading
Role of GBA variants in Lewy body disease neuropathology.
Walton, Ronald L; Koga, Shunsuke; Beasley, Alexandra I; White, Launia J; Griesacker, Teresa; Murray, Melissa E; Kasanuki, Koji; Hou, Xu; Fiesel, Fabienne C; Springer, Wolfdieter; Uitti, Ryan J; Fields, Julie A; Botha, Hugo; Ramanan, Vijay K; Kantarci, Kejal; Lowe, Val J; Jack, Clifford R; Ertekin-Taner, Nilufer; Savica, Rodolfo; Graff-Radford, Jonathan; Petersen, Ronald C; Parisi, Joseph E; Reichard, R Ross; Graff-Radford, Neill R; Ferman, Tanis J; Boeve, Bradley F; Wszolek, Zbigniew K; Dickson, Dennis W; Ross, Owen A; Heckman, Michael G.
Afiliação
  • Walton RL; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Koga S; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Beasley AI; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • White LJ; Division of Clinical Trials and Biostatistics, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, USA.
  • Griesacker T; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Murray ME; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Kasanuki K; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Hou X; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Fiesel FC; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Springer W; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Uitti RJ; Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
  • Fields JA; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
  • Botha H; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Ramanan VK; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Kantarci K; Department of Neuroradiology, Mayo Clinic, Rochester, MN, USA.
  • Lowe VJ; Department of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA.
  • Jack CR; Department of Neuroradiology, Mayo Clinic, Rochester, MN, USA.
  • Ertekin-Taner N; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Savica R; Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
  • Graff-Radford J; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Petersen RC; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Parisi JE; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Reichard RR; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Graff-Radford NR; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Ferman TJ; Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
  • Boeve BF; Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA.
  • Wszolek ZK; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Dickson DW; Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
  • Ross OA; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Heckman MG; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Acta Neuropathol ; 147(1): 54, 2024 03 12.
Article em En | MEDLINE | ID: mdl-38472443
ABSTRACT
Rare and common GBA variants are risk factors for both Parkinson's disease (PD) and dementia with Lewy bodies (DLB). However, the degree to which GBA variants are associated with neuropathological features in Lewy body disease (LBD) is unknown. Herein, we assessed 943 LBD cases and examined associations of 15 different neuropathological outcomes with common and rare GBA variants. Neuropathological outcomes included LBD subtype, presence of a high likelihood of clinical DLB (per consensus guidelines), LB counts in five cortical regions, tyrosine hydroxylase immunoreactivity in the dorsolateral and ventromedial putamen, ventrolateral substantia nigra neuronal loss, Braak neurofibrillary tangle (NFT) stage, Thal amyloid phase, phospho-ubiquitin (pS65-Ub) level, TDP-43 pathology, and vascular disease. Sequencing of GBA exons revealed a total of 42 different variants (4 common [MAF > 0.5%], 38 rare [MAF < 0.5%]) in our series, and 165 cases (17.5%) had a copy of the minor allele for ≥ 1 variant. In analysis of common variants, p.L483P was associated with a lower Braak NFT stage (OR = 0.10, P < 0.001). In gene-burden analysis, presence of the minor allele for any GBA variant was associated with increased odds of a high likelihood of DLB (OR = 2.00, P < 0.001), a lower Braak NFT stage (OR = 0.48, P < 0.001), a lower Thal amyloid phase (OR = 0.55, P < 0.001), and a lower pS65-Ub level (ß -0.37, P < 0.001). Subgroup analysis revealed that GBA variants were most common in LBD cases with a combination of transitional/diffuse LBD and Braak NFT stage 0-II or Thal amyloid phase 0-1, and correspondingly that the aforementioned associations of GBA gene-burden with a decreased Braak NFT stage and Thal amyloid phase were observed only in transitional or diffuse LBD cases. Our results indicate that in LBD, GBA variants occur most frequently in cases with greater LB pathology and low AD pathology, further informing disease-risk associations of GBA in PD, PD dementia, and DLB.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Doença por Corpos de Lewy / Doença de Alzheimer Limite: Humans Idioma: En Revista: Acta Neuropathol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Doença por Corpos de Lewy / Doença de Alzheimer Limite: Humans Idioma: En Revista: Acta Neuropathol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos